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Coronary artery disease (CAD) carries a high risk of mortality in dialysis patients. End-stage renal disease
is considered to increase the vulnerability of patients with atherosclerosis superimposed on artery
calciﬁcation. Recently, an increasing prevalence of CAD in dialysis patients has been attributed to a lack of
effective prevention and treatment. Further studies have shown that optimal therapies for CAD in dialysis
patients remain neglected and unclariﬁed. These therapies include correction of anemia, control of blood
pressure, and antiplatelet therapy. Because of bleeding tendencies in dialysis patients, the beneﬁts of
antiplatelet therapy and platelet glycoprotein IIb/IIIa inhibitors for treating CAD require more research. In
addition, a meta-analysis of retrospective studies in 2012 showed that dialysis patients with CAD
receiving coronary artery bypass surgery had a lower long-term mortality rate and fewer postoperative
cardiac complications than those receiving percutaneous coronary angioplasty. A large randomized,
long-term cohort study is necessary to conﬁrm these issues.
Copyright  2013, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Coronary artery disease (CAD) in patients with end-stage renal
disease (ESRD) contributes to high mortality, especially after acute
myocardial infarction [1e3]. The development of ESRD further
worsens the outcome of CAD, and the pathophysiology and course
of CAD differ in the presence of ESRD, such as with advanced
atherosclerosis superimposed on arterial calciﬁcation [4]. Coronary
revascularization in dialysis patients with CAD is rarely reported
and the optimal options are unclear [5].2. Risk factors for CAD in dialysis patients
The traditional risk factors for CAD in dialysis patients are hy-
pertension, diabetes, hyperlipidemia, left ventricular hypertrophy,
aging, smoking, and lack of physical activity [6e9]. Nontraditional
risk factors are uremic toxins, chronic inﬂammation, and abnormal
metabolism of calcium and phosphorus, which increase the
development of atherosclerosis and even calciﬁcation of theepartment of Internal Medi-
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ddhist Compassion Relief Tzu Chiarteries [10e12]. Therefore, prevention and therapy for CAD in
dialysis patients still require further clariﬁcation.
3. Diagnostic tools for dialysis patients with CAD
In addition to patient history and physical examination, other
commonly used noninvasive examinations are resting electrocardi-
ography, exercise electrocardiography, dobutamine stress echocar-
diography, adenosine- or dipyridamole-induced echocardiography,
exercise-induced stress nuclear scintigraphy, and vasodilation by
adenosine or dipyridamole-induced stress nuclear scintigraphy. Of
these, dobutamine stress echocardiography has the highest sensi-
tivity for CAD in patients with ESRD [13]. Furthermore, if CAD is
highly suspected in dialysis patients, invasive procedures such as
coronary angiography and coronary revascularization should be
done.
4. Medication for dialysis patients with CAD
4.1. Correction of anemia
Using erythropoiesis-stimulating agents and iron therapy, the
target level of plasma hemoglobin should be maintained in the
range of 11e12 g/dL in dialysis patients [14,15]. Because higher
hemoglobin levels could lead to a higher mortality rate, it isFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
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13 g/dL in dialysis patients [14,15].
4.2. Therapy guidelines for blood pressure, blood glucose, and blood
lipids
Hypertension in dialysis patients should ﬁrst be controlled by
removing excess body water. Moreover, if necessary, antihyper-
tensive drugs should be given to treat and prevent worsening of
CAD caused by long-term hypertension [15]. Beta-blockers can
reduce the incidence of arrhythmias and slow CAD progression,
particularly by reducing the incidence of myocardial infarction
[10]. Nitrates and calcium channel blockers cause vasodilation and
reduce angina. Angiotensin-converting enzyme inhibitors and
angiotensin II receptor blockers are also recommended for the
treatment of CAD, especially to decrease the mass of the left
ventricle without a higher statistical risk of hyperkalemia in
dialysis patients and heart failure [15,16]. The 2005 Kidney Dis-
ease Outcome Quality Initiative (K/DOQI) guidelines recommend
that blood pressure in dialysis patients should be maintained at
less than 140/90 mmHg before dialysis and less than 130/
80 mmHg after dialysis [15]. These guidelines also recommend
that the level of glycosylated hemoglobin (HbA1c) should not be
kept lower than 7.0% in dialysis patients with diabetes mellitus
who have frequent episodes of hypoglycemia [15]. However, strict
glycemic control may not beneﬁt dialysis patients [17,18], as
higher glucose and HbA1c levels are not associated with higher
mortality in dialysis patients [18]. The clinician is encouraged to
individualize glycemic targets based on the potential risks and
beneﬁts in diabetic patients undergoing dialysis [17]. The K/DOQI
guidelines recommend that the level of low-density lipoprotein
cholesterol should be less than 100 mg/dL and in dialysis patients
with a high risk of CAD it should be maintained at less than
70 mg/dL [15].
4.3. Antiplatelet therapy
Because dialysis patients have an increased risk of bleeding and
worsening arterial calciﬁcation, the beneﬁts and safety of aspirin
therapy for CAD in dialysis patients remain unclariﬁed. The use of
aspirin to decrease the risk of cardiovascular disease was not sup-
ported in a study of 28,320 randomly selected dialysis patients [19],
but this needs to be further investigated with randomized
controlled trials. Because of these concerns, the 2005 K/DOQI
guidelines recommend that aspirin treatment be based on the risk
and beneﬁts of individual cardiovascular diseases [15]. If necessary,
aspirin in low doses (81 mg/day) may be safe in dialysis patients
with CAD [15,20]. In addition, aspirin may be beneﬁcial only in
dialysis patients with acute coronary syndrome (ACS) [20,21].
4.4. Fibrinolytic agents, heparin, and platelet glycoprotein IIb/IIIa
inhibitors
There is a lack of favorable evidence for ﬁbrinolytic agents, high-
dose heparin, and platelet glycoprotein IIb/IIIa inhibitors to treat
ACS in dialysis patients [22] and these treatments could result in
signiﬁcant bleeding [23,24]. Because of this bleeding risk, ESRD
patients are excluded from clinical trials assessing the efﬁcacy of
platelet glycoprotein IIb/IIIa inhibitors [20]. If it is necessary to use
platelet glycoprotein IIb/IIIa inhibitors and there are no contrain-
dications, then abciximab and tiroﬁban are preferred, because
abciximab requires no dosing changes in dialysis patients and
dialysis-speciﬁc dosing recommendations are available for tiroﬁban
[24,25]. In contrast, eptiﬁbatide (platelet glycoprotein IIb/IIIa in-
hibitors) and enoxaparin (low molecular weight heparin) arecontraindicated in dialysis patients and are signiﬁcantly associated
with an increased risk of in-hospital major bleeding [26].
5. Invasive management of CAD in dialysis patients
5.1. Appropriate therapies for coronary revascularization
Dialysis patients with unstable CAD and ACS and a poor
response to medication may need to undergo coronary revascu-
larization, such as coronary artery bypass grafting (CABG) or
percutaneous coronary angioplasty (PTCA). Table 1 compares the
survival rates and the incidence of cardiac events in several studies
of dialysis patients with CAD undergoing PTCA and CABG. Early,
small, retrospective studies showed no difference in the mortality
of dialysis patients receiving CABG and PTCA [27e30]. However,
recent retrospective studies reported higher survival rates in dial-
ysis patients undergoing CABG than PTCA [31e34]. Two studies
from the US Renal Data System database showed that dialysis pa-
tients had a better survival rate after CABG than PTCA [35,36]. Re-
sults of most studies indicated a lower incidence of cardiac events
after CABG than PTCA [19,27,37]. These studies showed that dialysis
patients had a lower incidence of restenosis and postoperative
heart disease after CABG. Because of the low death rate after CABG
surgery, dialysis patients with serious CAD could undergo this
procedure [38]. The comparative survival of dialysis patients with
diabetes undergoing CABG and PTCA treatment is unclear, because
few studies have examined this issue. Barsness et al reported that
there was no signiﬁcant difference in survival rate after CABG and
PTCA in a 5-year longitudinal study of dialysis patients with dia-
betes [30]. However, in a 5-year retrospective analysis from the US
Renal Data System database, Herzog et al showed that dialysis
patients with diabetes had better survival rates after CABG than
PTCA [35]. A meta-analysis in 2012 showed that dialysis patients
had lower long-term mortality rate and a lower rate of cardiac
events after CABG than patients with PTCA, but large, randomized
cohort studies are still needed [39]. In short, the optimal therapy for
coronary revascularization in dialysis patients could depend on the
severity of CAD in an individual patient and the skill of the surgeon.
5.2. Choice of coronary stent
The prognosis according to stent type in dialysis patients is not
clear. Although there have been no randomized prospective
studies, several studies have shown that the rate of coronary
restenosis and revascularization was reduced in dialysis patients
with CAD who received drug-eluting stents (DESs) compared with
bare metal stents (BMSs) [40e42]. A comparison of the clinical
beneﬁts in dialysis patients with CAD undergoing coronary
stenting and CABG is presented in Table 2. The survival of dialysis
patients with coronary stenting compared with CABG remains
unclear. Two small recent studies showed no difference between
coronary stenting and CABG in dialysis patients [43,44]. However,
a large-population analysis from the US Renal Data System data-
base in 2002 showed that dialysis patients undergoing CABG had a
higher survival rate than those receiving coronary stenting [35].
However, this study was a retrospective analysis, and more clinical
random allocation studies are needed to conﬁrm the beneﬁts of
both procedures. Comparative outcomes of DESs and CABG in
dialysis patients are also indeﬁnite because of a lack of clinical
studies. One 5-year retrospective study indicated similar survival
outcomes in dialysis patients who had DESs and CABG [45].
However, a 2-year longitudinal study reported a better survival
rate with CABG than DESs in dialysis patients [46]. The AHA⁄ACC
guidelines state that aspirin and either clopidogrel or prasugrel
should be given for at least 12 months after patients with ACS
Table 1
Comparative outcome of survival rate and cardiac event-free survival rate between dialysis patients with CAD receiving PTCA and CABG.
Author (year) Design Years Group: Number Diseased vessels Outcome Cardiac event-free incidence
Barsness et al (1997) [30] Prospective 5 Diabetes: Diabetes: Five-year survival: P¼NS ND
PTCA: 144 PTCA: 22% triple vessel PTCA: 76%
CABG: 626 CABG: 71% triple vessel CABG: 74%
Non-diabetes: Non-diabetes: Five-year survival: P¼NS
PTCA: 560 PTCA: 19% triple vessel PTCA: 88%
CABG: 1890 CABG: 60% triple vessel CABG: 86%
Simsir et al (1998) [29] Retrospective 1.5 PTCA: 19 ND 1.5-Year survival: P¼NS 1.5-Year cardiac event-free
survival: P< 0.05
CABG: 22 PTCA: 69%. PTCA: 40%
CABG: 67% CABG: 87%
Herzog et al (1999) [36] Retrospective 10 PTCA: 6887 ND Two-year survival: P¼ 0.04 ND
CABG: 7419 PTCA: 52.9%
CABG: 56.9%
Agirbasli et al (2000) [28] Retrospective 10 PTCA: 122 PTCA: 27% triple vessel One-year mortality: P¼NS ND
CABG: 130 CABG: 56% triple vessel PTCA: 23%
CABG: 27%
Chertow et al (2000) [34] Retrospective 1 PTCA: 46 ND One-year survival: P¼ 0.03 ND
CABG: 29 PTCA: 54%
CABG: 69%
Szczech et al (2001) [33] Retrospective 3 PTCA: 163 PTCA: 11.1% triple vessel Three-year survival: P< 0.05 ND
CABG: 244 CABG: 63.1% triple vessel PTCA: 46.1%
CABG: 65.9%
Ivens et al (2001) [27] Retrospective 2 PTCA: 40 PTCA: 40% triple vessel One- and two-year
survival: P¼NS
One- and two-year cardiac
event-free survival: P< 0.001
CABG: 65 CABG: 62% triple vessel PTCA: 95% and 82% PTCA: 54% and 29%
CABG: 93% and 86% CABG: 94% and 90%
Baldovinos et al
(2002) [32]
Retrospective 3 PTCA: 28 ND Two-year survival: P< 0.05 ND
CABG: 23 PTCA: 69%
CABG: 82%
Hemmelgarn et al
(2004) [31]
Retrospective 8 PTCA: 147 PTCA: 48.3% triple vessel Eight-year survival: P¼ 0.003 ND
CABG: 153 CABG: 56.2% triple vessel PTCA: 41.2%
CABG: 44.8%
Fujimoto (2007) [37] Retrospective 5 PTCA: 81 ND One- and ﬁve-year survival:
P¼ 0.0065
One- and ﬁve-year cardiac
event-free survival: P< 0.001
CABG: 64 PTCA: 93.8% and 66.6% PTCA: 63.7% and 34.7%
CABG: 76.0% and 44.8% CABG: 83.2% and 66.8%
CABG¼ coronary artery bypass graft; CAD¼ coronary artery disease; ND¼ no data; NS¼ not signiﬁcant; PTCA¼ percutaneous coronary angioplasty.
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antiplatelet therapy in dialysis patients should be considered. The
ideal duration of this therapy is not known because of a lack of
randomized trials.Table 2
Comparative outcome of survival rate and cardiac event-free survival rate between dialy
Author (year) Design Years Group: Number Diseased
vessels
Outcom
Herzog et al
(2002) [35]
Retrospective 4 PTCA: 9116
Stent: 4280
CABG: 6668
ND Two-ye
PTCA: 4
Stent: 4
CABG:
*In diab
CABG v
*In diab
versus
Manabe et al
(2009) [44]
Retrospective 3 Stent: 12
CABG: 28
Stent : 22.2%
triple vessel
CABG: 75%
triple vessel
Two-ye
Stent: 7
CABG:
Sunagawa et al
(2010) [46]
Prospective 2 DES: 75
CABG: 29
ND 2-year
DES: 67
CABG:
Terazawa et al
2012 [45]
Retrospective 5 DES: 67
CABG: 58
Stent: 6%
triple vessel
CABG: 67%
triple vessel
One- a
DES: 88
CABG:
Yeates et al
2012 [43]
Prospective 2 Stent: 31
CABG: 24
ND One-ye
Stent: 6
CABG:
CABG¼ coronary artery bypass graft; CAD¼ coronary artery disease; DES¼ drug-elu
signiﬁcant.6. Summary
The optimal therapies for CAD in dialysis patients include
correction of anemia (11e12 g/dL) to reduce hypoxia, maintainingsis patients with CAD receiving coronary stenting and CABG.
e Cardiac event-free incidence
ar survival: P< 0.0001
8.2%
8.4%
56.4%
etes, relative mortality of
ersus PTCA was 0.81 (P< 0.0001)
etes, relative mortality of stent
PTCA was 0.99 (P> 0.05)
* In diabetes, relative cardiac mortality
of CABG versus PTCA was 0.71 (P< 0.0001)
* In diabetes, relative cardiac mortality
of stent versus PTCA was 0.99 (P> 0.05)
ar survival: NS, P¼ 0.41
3.9%
94.1%
Two-year cardiac event-free: P¼ 0.001
Stent: 37.1%
CABG: 85.9%
survival: P¼ 0.0271
.6%
84.0%
Two-year cardiac event-free: P< 0.0001
DES: 31.5%
CABG: 75.8%
nd ﬁve-year survival: NS, P¼ 0.202
.2% and 61.7%
84.2% and 56.2%
One- and ﬁve-year cardiac event-free:
P< 0.001
DES: 63.0% and 0%
CABG: 76.6% and 48.6%
ar mortality: NS, P¼ 0.28
%
29%
ND
ting stents; PTCA¼ percutaneous coronary angioplasty; ND¼ no data; NS¼ not
C.-L. Chou, T.-C. Fang / Tzu Chi Medical Journal 25 (2013) 82e85 85blood pressure less than 140/90 mmHg before dialysis and 130/
80 mmHg after dialysis, controlling low-density lipoprotein
cholesterol level at less than 100mg/dL, antiplatelet therapy if there
are no clinical contraindications, and coronary revascularization if
dialysis patients have unstable CAD or ACS. Ameta-analysis study in
2012 showed that dialysis patients have a lower long-term mor-
tality rate and fewer cardiac events after CABG than PTCA, but this
merits investigation in large, randomized cohort studies.References
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